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Abstract
Outcome following traumatic brain injury (TBI) is in large part determined by the combined action
of multiple processes. In order to better understand the response of the central nervous system to
injury, we utilized an antibody array to simultaneously screen 507 proteins for altered expression in
the injured hippocampus, a structure critical for memory formation. Array analysis indicated 41
candidate proteins have altered expression levels 24 hours after TBI. Of particular interest was
catechol-O-methyl transferase (COMT), an enzyme involved in metabolizing catecholamines
released following neuronal activity. Altered catecholamine signaling has been observed after brain
injury, and may contribute to the cognitive dysfunctions and behavioral deficits often experienced
after TBI. Our data shows that COMT expression in the injured ipsilateral hippocampus was elevated
for at least 14 days after controlled cortical impact injury. We found strong co-localization of COMT
immunoreactivity with the microglia marker Iba1 near the injury site. Since dopamine transporter
expression has been reported to be down-regulated after brain injury, COMT-mediated
catecholamine metabolism may play a more prominent role in terminating catecholamine signaling
in injured areas.
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INTRODUCTION
The central nervous system (CNS) response to trauma is complex, and involves axonal injury,
cell death, neuronal dysfunction, impaired plasticity and altered neurotransmission. Since
outcome after traumatic brain injury (TBI) is dependent on the combined action of a diverse
assortment of gene products, global analysis of alterations in mRNA and protein expression is
likely to provide a better overall description of TBI pathophysiology [5,6,12]. In this study,
we used an antibody array as a first pass screen to identify potential candidate proteins whose
expression levels change in the rat hippocampus 24 h after TBI. After validating altered
expression of representative candidates by western blot analysis, we subsequently targeted
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catechol-O-methyl transferase (COMT), an enzyme involved in the metabolism of the
catecholamines dopamine and norepinephrine, for a more extensive characterization.
Numerous studies have indicated that catecholamine signaling (e.g. synthesis, release,
reuptake/inactivation) can be disturbed after TBI, suggesting that altered catecholamine
function may play a role in some of the behavioral deficits observed after TBI [15,17,18,30].
For example, TBI in rats results in increased expression of tyrosine hydroxylase (TH) protein,
the rate-limiting enzyme in catecholamine synthesis, as well as norepinephrine and dopamine
content [16,28]. In addition, Yan et al. demonstrated decreased expression of the dopamine
transporter after TBI, which may affect reuptake and signaling termination [29]. In humans,
some cognitive functions correlate with a genetic polymorphism that determines COMT
enzyme activity, while COMT-deficient mice exhibit altered behavior and regional
disturbances in dopamine level [1,7,10]. Since TBI alters pathways involved in catecholamine
synthesis and extracellular clearance, a better understanding of changes in the pathways
involved in catecholamine metabolism would aid in the understanding of TBI pathophysiology
and in designing potential treatment paradigms.
METHODS
Materials
Harlan (Indianapolis, IN) provided male Sprague-Dawley rats (250–300g). Cy3/Cy5
monofunctional NHS-ester labeling kits were from Amersham Biosciences (Piscataway, NJ).
Antibody arrays and mouse anti-COMT, -AF6, -CA150, -Ngn3, and -glutamine synthetase
were obtained from BD Biosciences (San Jose, CA). Rabbit anti-GAD65/67, -GFAP, -GalC, -
parvalbumin, and -NF-H were from Chemicon (Temecula, CA), and -Iba1 was from WAKO
USA (Richmond, VA). Fluorescent secondaries were from Molecular Probes (Eugene, OR),
and Vector Labs (Burlingame, CA) provided AP-conjugated secondaries.
Cortical Impact Injury
All protocols involving animals are in compliance with NIH's Guide for the Care and Use of
Laboratory Animals and approved by the Institutional Animal Care and Use Committee. A
controlled cortical impact device was used to administer unilateral brain injury at 1.9 mm
deformation essentially as described in [25]. Sham rats received a midline incision but were
not otherwise injured.
Protein labeling, antibody array processing, and data handling
Rats were decapitated 24 h after injury (n=5) or sham surgery (n=4) and the hippocampi
removed under ice-cold artificial cerebrospinal fluid. Cytosolic extracts from individual
hippocampi were prepared in 500 μl buffer containing 10 mM HEPES pH 7.5, 1 mM EDTA,
1 mM EGTA, 10 mM NaF, 2 mM sodium pyrophosphate, 25 mM β-glycerophosphate, 1 mM
DTT, 1 mM diisopropyl fluorophosphate, 100 nM okadiac acid, and 1 mM sodium
orthovanadate. Extracts were centrifuged 10 min, 4°C, 10,000 x g, and the supernatant
recovered and quantified by Bradford assay. All subsequent steps were carried out as described
by in the manufacturers’ protocols. Equal amounts of sham or injured protein extracts were
pooled and labeled with Cy3- or Cy5-NHS ester dyes to generate four labeled samples: TBI-
Cy3, TBI-Cy5, Sham-Cy3, and Sham-Cy5. The labeled samples were purified, and the dye/
protein ratio measured. Arrays were incubated with 20 μg labeled sample mixes (forward: TBI-
Cy5/Sham-Cy3; reverse: Sham-Cy5/TBI-Cy3), sequentially washed with buffers 1–7,
centrifuged 25 min at 1000 x g, and imaged on an Axon Genepix 4200A slide scanner at 10
μm resolution.
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Western blot
Sham and 24 h injured ipsilateral hippocampal cytosolic extracts were prepared as described
in [17]. Total extracts were prepared from sham, 3 d and 14 d samples by solubilizing
hippocampi in 10 volumes lysis buffer [6 M urea, 2 M thiourea, 2% CHAPS, and 65 mM DTT].
Equal amounts of protein were separated by SDS-PAGE, blotted, and probed with the
following antibodies: mouse anti-COMT (1:10,000), anti-glutamine synthetase (1:10,000),
anti-AF6 (1:500), anti-Ngn3 (1:500) and anti-CA150 (1:250). Blots were developed using
CPD-Star, and the resulting images quantified using ImageJ.
Immunohistochemistry
Immunohistochemical detection of target proteins was carried out as previously described
[25], except picric acid was omitted. Immunoreactivity was detected using anti-mouse IgG-
Alexa-568 and anti-rabbit IgG-Alexa-488. Images were collected using a Bio-Rad MRC 1024
confocal microscope with an Olympus BX 50W camera.
Data analysis and statistics
Western blot data were compared using 2-tailed unpaired Student’s t-test, and considered
significant at p < 0.05. The Ab array data was analyzed using two methods. First, we analyzed
the fluorescent intensity signal using the manufacturer’s suggested protocol (internally
normalized ratio, INR) by taking the square root of each protein’s averaged forward and reverse
ratios [√(TBI-Cy5/Sham-Cy3)/(Sham-Cy5/TBI-Cy3)]. We then applied the Rank Product
method [3] as outlined in Srivastava et al. [27]. Calculated RP values were converted to
approximate expected values (E, analogous to BLAST expected values) as described in [3].
Briefly, we performed 100 simulated experiments with the same parameters as the Ab array,
used a random number generator to obtain spot values, and determined the number of times a
simulated RP value smaller than a given experimental value occurred. We used E <0.05 as the
cutoff to determine which candidates had altered expression. To minimize potential false
positives, we only considered proteins meeting both analyses threshold criterion as potential
candidates.
RESULTS
Antibody array
To control for differences in protein quantification and labeling efficiency, reciprocally labeled
aliquots of sham and TBI extract mixes were incubated on replicate arrays. Figure 1A shows
a representative Ab array region incubated with the fluorescently-labeled extract mixes.
Proteins exhibiting no change in expression between sham and TBI groups appear yellow,
while proteins with altered expression appear red or green. The array had low overall
background, and duplicate spots had similar signal intensities. After scanning, the average
internally normalized ratio (INR) was calculated for each protein. As recommended by
previous investigators, proteins with INRs >1.35 or <0.75 were considered to have different
expression levels [2]. We then reanalyzed the data set using Rank Product (RP) analysis [3].
RP analysis has been suggested to provide a more robust and statistically accurate methodology
for comparing proteomic data sets than the manufacturer recommended INR analysis [27].
Proteins exhibiting differential expression between sham and TBI groups by both INR and RP
analysis were considered potential candidates, and are listed in Table 1.
Candidate verification
To independently validate some of the antibody array results, we randomly chose two candidate
proteins (AF6, CA150) for western blot analyses. To test selection criteria robustness,
glutamine synthetase and neurogenin-3 were also tested because, unlike CA150 and AF6, they
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met only one analysis methodology criteria and therefore were not considered potential
candidates. Figure 1B-D shows representative western blots and summary results for the
expression levels of AF6, CA150, and glutamine synthetase. Neurogenin-3 expression was not
quantifiable, suggesting its array signal may have resulted from non-specific binding. Also
consistent with exclusion as a candidate, glutamine synthetase expression level was not
significantly different between sham and 24 h TBI groups (Fig. 1B). However, western blot
analysis found significantly decreased expression of both AF6 (Fig. 1C) and CA150 (Fig. 1D)
24 h after injury, consistent with the Ab array data. These results suggest the proteins included
in Table 1 are viable candidates with altered expression levels after TBI.
Time course and localization of COMT expression after injury
Since a number of studies have indicated that altered catecholamine signaling may contribute
to TBI-associated cognitive dysfunction, COMT was selected for further examination [15–
17,20,30]. As shown in figure 2A, analysis of 24 h cytosolic extracts showed a mean increase
in soluble COMT expression after injury, similar to the results obtained from the Ab array.
COMT is expressed as soluble (S) and membrane-bound (MB) isoforms that are derived from
a single gene, though expression is regulated by independent promoters [19]. Therefore, we
generated additional total protein extracts to assess possible differential regulation of COMT
isoforms. We selected 3 d and 14 d post-injury since these times have been previously
demonstrated to exhibit TBI-associated behavioral effects. As shown by the representative
blots and summary data (Fig. 2), analysis of 3 and 14 d hippocampal total protein extracts
showed significant alterations in both S- and MB-COMT isoform expression. Summary results
of S-COMT showed significantly elevated ipsilateral expression at both 3 d and 14 d post-TBI.
Interestingly, contralateral S-COMT was differentially regulated, with increased expression at
3 d but decreased expression at 14 d (Fig. 2C). Ipsilateral MB- COMT was significantly
elevated at both 3 and 14 days post-TBI, while contralateral expression was increased only at
3 d (Fig. 2D).
Immunohistochemical identification of COMT-expressing cells
COMT expression has been reported in a wide variety of CNS cell types, including neurons,
astrocytes, microglia, vascular endothelium, and ependymal cells. Immunohistochemical
staining of uninjured sham sections indicated broadly distributed low-level COMT
immunoreactivity throughout the hippocampus (not shown). The most striking change in
COMT localization following TBI was a large increase in intensely labeled COMT-positive
cells throughout the ipsilateral injured hippocampus observed at both 3 and 14 days post-injury.
In order to identify this cell population, we performed double immunohistochemical staining
(Fig. 3A) using 14 d post-injury tissue sections. The intense COMT immunoreactivity did not
co-localize with cells expressing NF-H (neuron), GFAP (astrocyte), GalC (oligodendrocyte,
not shown), GAD65/67 or parvalbumin (inhibitory interneuron, not shown). However, we
detected co-localization between COMT immunoreactivity and Iba1, which detects both
quiescent and activated microglia.
To further investigate the changes in COMT expression, we co-labeled sections from various
time points post-TBI with anti-COMT and -Iba1 antibodies. Control sections incubated without
primary antibodies had no detectable signal (not shown). Sham sections showed evenly
distributed ramified Iba1-positive microglia with low level COMT expression (Fig. 3B).
Within 24 h after injury, there is an apparent increase in Iba1+/COMT+ activated (amoeboid)
microglia throughout the ipsilateral hippocampus. By 3 d post-TBI, when western blots
detected the largest increase in COMT expression, there is a substantial increase in ispilateral
hippocampal Iba1+ amoeboid microglia also expressing intense COMT immunoreactivity. In
contrast, there was no noticeable increase in either the number or activation state of
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contralateral hippocampal microglia, indicating the changes in COMT expression are largely
confined to the ipsilateral hemisphere. Fourteen days after injury, the Iba1+ microglial
population in the ipsilateral hippocampus remained significantly elevated, though the co-
localized COMT staining intensity appeared reduced, consistent with the western blot data.
DISCUSSION
Protein discovery using 2-D gel and mass spectrometry proteomic approaches have aided in
deciphering the complex biochemical changes following TBI. [6,11,12]. These approaches,
although informative, require specialized expertise and equipment. Antibody arrays, however,
provide a target-directed methodology that facilitates high-throughput screening of large
numbers of known or suspected candidate proteins. The antibody array analysis presented in
this study identified 41 candidates whose hippocampal expression levels were significantly
altered 24 h after injury, indicating the complexity of the brain’s response to TBI.
Previous studies of individually selected proteins, as well as global gene chip analysis, have
indicated the involvement of many different proteins in TBI pathophysiology (for review, see
[5]). Although some candidates may also appear within DNA microarray data sets, literature
searches revealed at least 9 of the candidates in Table 1 have been specifically implicated in
injury models or injury-activated pathways. For instance, the increased hypoxia-inducible
transcription factor (Hif-1α) protein after TBI is consistent with altered Hif-1α mRNA after
TBI [24], and increased protein expression after ischemic and brain hemorrhage injury [13,
22]. Gao et al. recently reported a significant decrease in H3 histone acetylation levels after
TBI [9]. This is consistent with increased SMRT expression, a central component of a co-
repressor complex that recruits histone deacetylase to the promoter regions of genes [23]. These
data, in conjunction with our confirming altered AF6 and CA150 expression (Fig. 1), indicate
a high-throughput characterization of protein expression approach using Ab arrays may
successfully identify potential candidates involved in TBI pathophysiology.
In the present study, the selection of COMT for a more detailed analysis was guided by a
number of previous studies that have implicated catecholamine signaling in the behavioral
sequelae of TBI [4,20,21]. Following their release, catecholamines are either taken up by
specific transporters and/or are metabolized by monoamine oxidase or COMT. Transporter-
mediated termination of catecholamine signaling plays a prominent role in structures such as
the striatum, whereas in structures such as the prefrontal cortex that express low transporter
levels, inactivation through metabolism may play a more prominent role [14,26]. An increased
role for COMT after injury is consistent with the reported decrease in dopamine transporter
(DAT) as early as 7 d post-injury, and increases in the levels of TH protein and TH fibers in
the frontal cortex [16,28,29]. Western blot data (Fig. 2) indicated significant changes in COMT
isoform expression occurred in both hemispheres at both 3 and 14 d post-TBI. These data may
reflect changes in COMT expression in a wide variety of cell types, including vascular
endothelial, microglial and neuronal cell types. Our double immunohistochemical-labeling
experiments (Fig. 3) indicate that at all time points post-injury, microglia in the ipsilateral
injured area exhibit enhanced COMT expression. In addition, increased COMT
immunoreactivity in the dentate gyrus, hilus, and fiber tracts was also observed. Interestingly,
recent research has shown that microglia express dopamine receptor mRNA, and their
migration can be stimulated by the application of dopamine, the D1 receptor agonist
dihydrexidine, or the D2 receptor agonist quinpirole [8]. It is possible that increased dopamine
release after injury [20] might serve as a chemotactic signal to trigger the recruitment of
microglia to distressed regions.
Since scavenging is one of the primary microglia roles in the CNS, enhanced microglia COMT
expression may aid in removing and metabolizing catecholamines from damaged areas.
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Alternatively, the increased COMT immunoreactivity detected in the activated microglia (Fig.
3) might arise from phagocytic activity as they clean the debris from the dead and dying cells
in the injured hippocampus. However, elevated COMT immunoreactivity is still associated
with microglia at 14 days post-injury. This would indicate that intrinsically up-regulated
COMT expression in microglia is a more likely explaination, since phagocytosed COMT would
not be expected to remain stable over long periods. Additional experiments are needed to
determine the exact mechanism (transcription, translation, or protein stability) through which
microglia regulates COMT expression, and its consequences following TBI.
In conclusion, the present study demonstrates the potential of Ab arrays to explore the complex
pathophysiology of CNS injury. In addition to corroborating previous studies, the antibody
array identified many novel candidate proteins. For instance, 10 of the 41 candidates possess
functions related to actin dynamics, remodeling, or cell adhesion. Since blood-brain barrier
integrity is compromised following TBI, defining the changes that occur in tight junction
proteins (e.g. AF6, symplekin) or signaling proteins that regulate actin dynamics (e.g. PRK2,
ILK, ABR, Rho-GDI 2) may be critical to understanding the mechanisms underlying blood-
brain barrier dysfunction. Some of these candidates may also be involved structural remodeling
after TBI. The identification of altered COMT expression, in addition to other novel candidates,
may be useful for developing therapies to improve TBI outcome.
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Fig. 1.
Hippocampal COMT protein expression is increased after TBI. (A) Representative antibody
array region incubated with labeled forward (top) and reverse (bottom) 24 h cytosolic extract
mixes. Unchanged proteins appear yellow, while red or green coloration indicates altered
expression level. (B–D) Western blot verification of selected candidate proteins.
Representative gel image of (B) glutamine synthetase, (C) AF6, and (D) CA150
immunoreactivity detected in cytosolic extracts are shown above, with the summary results
depicted in the associated bar graphs shown below. s-sham (N=4); i-injured (N=5). Asterisks
(*) indicate p<0.05.
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Fig. 2.
Ipsilateral hippocampal COMT expression levels are chronically altered after TBI. (A)
Representative soluble COMT immunoreactivity western blot images detected in 24 h sham
and TBI cytosolic extracts, with the summary results shown below. (B) Representative western
blot images of total protein extracts from 3 d and 14 d samples detecting both soluble (s, 24
kDa) and membrane-bound (mb, 28 kDa) COMT isoforms. (C) Summary results of changes
in ipsi- and contralateral hippocampal soluble COMT immunoreactivity. (D) Summary results
of changes in ipsi- and contralateral hippocampal membrane-bound COMT immunoreactivity.
Symbols are as follows: open bars-sham; ; shaded, no hatching-ipsilateral; shaded, hatched-
contralateral. Marker in (A–B) is 25 kDa. Asterisks (*) indicate p<0.05.
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Fig. 3.
Increased COMT immunoreactivity in the injured hippocampus co-localizes with the microglia
marker Iba1. (A) Representative high magnification confocal images demonstrating COMT
immunoreactivity (red) in the ipsilateral hippocampi of 14 d TBI animals co-labeled (green)
with (left) NF-H, (middle) GFAP, or (right) Iba1. (B) Representative confocal images
showing Iba1 immunoreactivity (left, green), COMT immunoreactivity (middle, red) and
merged images (right) at various times after injury. Dashed line delineates the margin between
the dentate granule cell layer (upper, left) and the hilus (bottom, right). (C) Representative
images of COMT-Iba1 co-localization in the CA1, but separate staining in the lateral ventricle
(LV) and hippocampal blood vessel (v). Arrows indicate representative co-labeled cells,
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asterisks indicate no co-labeling. Areas with overlapping immunoreactivity appear yellow. The
scale bars in (A) and (B–C) represent 10 and 30 μm, respectively.
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Redell and Dash Page 13
Protein Swiss Prot Putative function
Increased
 Bcat,ab P54687 Cell cycle regulation, apoptosis
 CK Iε P49674 Ser/thr protein kinase
 Cdk4c P11802 Cell cycle regulation
 COMT P21964 Catecholamine o-methylation
 CRP1d P21291 Actin bundling
 CSK P41240 Tyrosine kinase
 Dematind Q08495 Actin bundling
 GRAP 2 O75791 Kinase signaling adaptor protein
 GRB14 Q14449 Receptor-mediated signaling
 HIF-1α,ac Q16665 Hypoxia-regulated transcription
 hRAD9 Q99638 Cell cycle control checkpoint
 HSF4 Q9ULV5 Heat shock gene transcription
 IGFBP-3,abc P17936 Growth factor signaling
 IL-5 P05113 Cytokine signaling
 ILKd Q13418 Integrin-mediated signaling
 MCP-1,abc P13500 Chemokine
 p67 phoxa P19878 Superoxide anion production
 PDE5A O76074 cGMP phosphodiesterase
 Pleckstrind P08567 PKC substrate
 PRK2d Q16513 Ser/thr protein kinase
 RanBP3 O75759 Nuclear export
 Ref-1a P27695 DNA repair
 Rho-GDI 2d P52566 Actin dynamics
 SMRTb Q9Y618 Chromatin structure
 SRP54 P13624 Signal sequence recognition
 Symplekind Q92797 Tight junction/RNA maturation
 TEF-1 P28347 Transcriptional enhancer
 TOP IIα P11388 DNA structure
Decreased
 ABRd Q12979 GTPase activating protein
 AF6/afadind P55196 Tight/adherens junction
 CA150 O14776 Transcription/splicing regulator
 CDC37 Q16543 Protein targeting
 Contactin/F3d Q12860 Cell adhesion
 DHFR P00374 Folate metabolism
 E1A BP Q09472 Transcription co-activator
 E2F-1 Q01094 Transcription factor
 EBP50d Q9JJ19 Actin scaffolding protein
 GSPT2 Q9NY44 Translation termination
 Rab 4 P20338 Endocytosis/vesicle trafficking
 SCP3 P70281 Chromosome alignment
 SRPK1a Q12890 Localization of splicing factors
a
Proteins identified in related injury models
b
Proteins involved in associated pathways
c
Proteins previously implicated in TBI
d
Novel candidates potentially involved in structural remodeling
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